Company Overview
| Stock Name | JBM Healthcare |
|---|---|
| Stock Code | 02161 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們為總部設於香港的領先品牌醫療保健品推廣及分銷公司,產品據點遍及大中華、東南亞及其他選定國家。產品組合包括消費者醫療保健品(品牌藥及健康保健品)及品牌中藥(非處方品牌中藥及濃縮中藥顆粒產品)。 |
| Listing Date | 2021-02-05 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港九龍觀塘觀塘道388號創紀之城1期1座23樓2303-07室 |
| Business Address (Hong Kong) | 香港九龍觀塘觀塘道388號創紀之城1期1座23樓2303-07室 |
| Place of Incorporation | 中国 |
| Listing Method | 全球发售 (公开发售 + 国际配售) |
| Listing Board | Main Board |
| Website | jbmhealthcare.com.hk |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 1.20 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 2,000 shares |
| Entry Threshold | HK$ 2,400 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2026-06-05 to 2026-06-10 |
| Global Offering Shares | 11,464,100 shares |
| HK Public Offer Shares (Initial) | 1,146,500 shares (10.0%) |
| Public Offer Lots (Initial) | 573lots (Pool A286lots,Pool B287lots) |
| International Placing Shares (Initial) | 10,317,600 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 893,686,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 13,756,920 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 2,000 | HK$ 2,400 |
| 2 lots | 4,000 | HK$ 4,800 |
| 3 lots | 6,000 | HK$ 7,200 |
| 4 lots | 8,000 | HK$ 9,600 |
| 5 lots | 10,000 | HK$ 12,000 |
| 6 lots | 12,000 | HK$ 14,400 |
| 7 lots | 14,000 | HK$ 16,800 |
| 8 lots | 16,000 | HK$ 19,200 |
| 9 lots | 18,000 | HK$ 21,600 |
| 10 lots | 20,000 | HK$ 24,000 |
| 15 lots | 30,000 | HK$ 36,000 |
| 20 lots | 40,000 | HK$ 48,000 |
| 25 lots | 50,000 | HK$ 60,000 |
| 30 lots | 60,000 | HK$ 72,000 |
| 35 lots | 70,000 | HK$ 84,000 |
| 40 lots | 80,000 | HK$ 96,000 |
| 45 lots | 90,000 | HK$ 108,000 |
| 50 lots | 100,000 | HK$ 120,000 |
| 100 lots | 200,000 | HK$ 240,000 |
| 150 lots | 300,000 | HK$ 360,000 |
| 200 lots | 400,000 | HK$ 480,000 |
| 250 lots | 500,000 | HK$ 600,000 |
| 300 lots | 600,000 | HK$ 720,000 |
| 350 lots | 700,000 | HK$ 840,000 |
| 400 lots | 800,000 | HK$ 960,000 |
| 450 lots | 900,000 | HK$ 1,080,000 |
| 500 lots | 1,000,000 | HK$ 1,200,000 |
| 1,000 lots | 2,000,000 | HK$ 2,400,000 |
| 1,500 lots | 3,000,000 | HK$ 3,600,000 |
| 2,000 lots | 4,000,000 | HK$ 4,800,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,500 lots | 5,000,000 | HK$ 6,000,000 |
| 3,000 lots | 6,000,000 | HK$ 7,200,000 |
| 4,500 lots | 9,000,000 | HK$ 10,800,000 |
| 5,000 lots | 10,000,000 | HK$ 12,000,000 |
| 11,171 lots | 22,342,000 | HK$ 26,810,400 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.74B |
| Est. Threshold | HK$ 9.44B |
| Analysis Result | HK market cap below threshold, need +441% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 1,072,423,200 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約44.3百萬港元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 43,000,000 |
| Listing Expenses / Funds Raised | ~312.57% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
HKD
Income Statement
| Item | 2018-03 | 2019-03 |
|---|---|---|
| Revenue | 86,004 | 100,747 |
| Cost of sales | -44,330 | -53,741 |
| Gross profit | 41,674 | 47,006 |
| Other income and gains, net | 13 | 38 |
| Administrative expenses | -16,927 | -20,761 |
| Operating profit | 24,760 | 26,283 |
| Net finance costs | -43 | -117 |
| Profit before tax | 24,717 | 26,166 |
| Income tax expense | -4,054 | -4,119 |
| Profit for the year | 20,663 | 22,047 |
Balance Sheet
| Item | 2018-03 | 2019-03 |
|---|---|---|
| Cash and cash equivalents | 9,806 | 23,155 |
| Trade and bills receivables | 8,865 | 9,627 |
| Inventories | 16,424 | 11,649 |
| Total current assets | 35,095 | 44,431 |
| Total current liabilities | 16,626 | 19,541 |
| Total equity | 20,663 | 28,027 |
Cash Flow Statement
| Item | 2018-03 | 2019-03 | 2019-08 |
|---|---|---|---|
| Net cash from operating activities | 18,832 | 30,859 | |
| Net cash from investing activities | -484 | -312 | |
| Net cash from financing activities | -18,275 | -17,198 | |
| Net increase in cash | 73 | 13,349 | |
| Depreciation of PP&E | 170 | 186 | 60 |
| Depreciation of right-of-use assets | 616 | 2,431 | 1,744 |
| Purchase of PP&E | -486 | -318 | -11 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 2.16 |
|---|---|
| First Day Open | HK$ 1.48 |
| First Day Change | 80.00% |
| First Day Volume | 340448000.0 |
| First Day Turnover | 756998000.0 |
| Use of Proceeds | 1、約47.2%或約5.0百萬港元為品牌中藥的產品組合開發及品牌管理提供資金;
2、約43.4%或約4.6百萬港元為自第三方品牌擁有人獲取額外分銷權的付款提供資金;
3、約9.4%或約1.0百萬港元補充我們的營運資金及用于一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
中国银河国际证券(香港)有限公司 CE AXM459
Joint Bookrunners (1)
中国银河国际证券(香港)有限公司 CE AXM459
Joint Lead Managers (8)
中国银河国际证券(香港)有限公司 CE AXM459
CINDA INTERNATIONAL CAPITAL LIMITED CE AEE541
Eddid Securities and Futures Limited CE BHT550
Fosun International Securities Limited CE AAF432
SILVER NILE GLOBAL INVESTMENTS LIMITED CE BJB477
迈时资本有限公司 CE BNO600
SOUTHWEST SECURITIES (HK) BROKERAGE LIMITED CE ACB501
TUS Corporate Finance Limited CE BJL235
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 岑廣業 | — |
| Company Secretary | 歐敏兒 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 緊隨分拆完成後,控股股東JBM Group BVI持有約53.74%股權;最終控股股東岑先生控制約69.67%權益;Lincoln’s Hill持有約11.90%。 |
|---|




